Cosmos Health Inc. (COSM)
(Real Time Quote from BATS)
$1.08 USD
+0.08 (7.46%)
Updated Sep 17, 2024 02:52 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Price, Consensus and EPS Surprise
COSM 1.08 +0.08(7.46%)
Will COSM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for COSM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for COSM
MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates
Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates
COSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates
Other News for COSM
Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price
Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.
Cosmos Health secures exclusivity agreement with Virax Biolabs
Virax Biolabs extends distribution agreement to market Mpox detection kits
Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar